Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: Does stent diameter matter? Three-year follow-up of BASKET

European Heart Journal

Volumn 30, Issue 1, 2009, Pages 16-24

  Pfisterer, Matthias ^a   Brunner La Rocca, Hans Peter ^a   Rickenbacher, Peter ^b   Hunziker, Patrick ^a   Mueller, Christian ^a   Nietlispach, Fabian ^a   Leibundgut, Gregor ^a   Bader, Franziska ^a   Kaiser, Christoph ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b Bruderholzspital ^*  (Switzerland)

Author keywords

Bare metal stents; Coronary artery disease; Drug eluting stents; Outcome; Stent thrombosis

Indexed keywords

ADULT; ARTICLE; BARE METAL STENT; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; STENT DIAMETER; STENT THROMBOSIS; TARGET VESSEL REVASCULARIZATION; VASCULAR DISEASE;

AGED; BLOOD VESSEL PROSTHESIS IMPLANTATION; CARDIOVASCULAR AGENTS; CORONARY STENOSIS; CORONARY VESSELS; DRUG-ELUTING STENTS; EQUIPMENT DESIGN; FEMALE; FOLLOW-UP STUDIES; GRAFT OCCLUSION, VASCULAR; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; STENTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 58149265063     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn516     Document Type: Article

References (28)

1. Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-2591.
2. Williams DO, Abbott JD, Kip KE. Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation 2006;114:2154-2162.
3. Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
4. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-997.
5. Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabaté M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schömig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-1039.
6. Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HH, Bottcher M, Lassen JF, Krussel LR, Rasmussen K, Hansen KN, Pedersen L, Johnsen SP, Soerensen HT, Thuesen L. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 2007;50:463-470.
7. Schoemig A, Dibra A, Windecker S, Mehilli J, Suarez de Lezo J, Kaiser C, Park SJ, Goy JJ, Lee JH, Di Lorenz E, Wu J, Jüni P, Pfisterer ME, Meier B, Kastrati A. A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary disease. J Am Coll Cardiol 2007;50:1373-1380.
8. Percoco G, Manari A, Guastaroba P, Campo G, Guiducci V, Aurier E, Sangiorgio P, Passerini F, Geraci G, Piovaccari G, Naldi M, Saia F, Marzocchi A, Real Investigators. Safety and long-term efficacy of sirolimus eluting stents in ST-elevation acute myocardial infarction: the REAL registry. Cardiovasc Drugs Ther 2006;20:63-68.
9. Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schömig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabaté M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, trelle S, Windecker S, Jüni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-948.
10. Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019.
11. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Blackhouse G, Lazzam C, Cohen EA, Goeree R. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-1402.
12. Brunner-La Rocca HP, Kaiser C, Pfisterer M BASKET Investigators. Targeted stent use in clinical practice based on evidence from BASKET. Eur Heart J 2007;28:719-725.
13. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Jüni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PV. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-678.
14. Brunner-La Rocca HP, Kaiser C, Bernheim A, Zellweger MJ, Jeger R, Buser PT, Osswald S, Pfisterer M BASKET Investigators. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in BASKET: an 18-month analysis. Lancet 2007;370:1552-1559.
15. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranchx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007;115:2344- 2351.
16. Kaiser C, Brunner-La Rocca HP, Buser PT, Bonetti PO, Osswald S, Linka A, Bernheim A, Zutter A, Zellweger M, Grize L, Pfisterer ME BASKET Investigators. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005;366:921- 929.
17. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007;26:2389-2430.
18. Eisenstein EL, Anstrom KJ, Kong FD, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulmann KA, Califf RM. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007;297:159-168.
19. Zellweger M, Kaiser C, Brunner-La Rocca HP, Buser PT, Osswald S, Weiss P, Mueller-Brand J, Pfisterer ME BASKET Investigators. Value and limitation of target vessel ischemia to predict late clinical events after drug eluting stent implantation. J Nucl Med 2008;49:1-7.
20. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini PA. Sirolimus-eluting versus uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004;292:2727-2734.
21. Lüscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, Tanner FC, Virmani R. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007;115:1051-1058.
22. Airoldi F, Colombo A, Morici N, Latib A, Cosgrave J, Buellesfeld L, Bonizzoni E, Carlino M, Gerckens U, Godino C, Melzi G, Michev I, Montorfano M, Sangiorgi GM, Qasim A, Chieffo A, Briguori C, Grube E. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-754.
23. Grines CL, Bonow RO, Casey DE, Gardner TJ, Lockhart PB, Moliterno DJ, O'Gara P, Whitlow P American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography Interventions, American College of Surgeons, American Dental Association, American College of Physicians. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Circulation 2007;115:813-818.
24. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
25. Serruys PW, Daemen J, Morice MC. Three-year follow-up of the ARTS-II - sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. EuroInterv 2007;3:450-459.
26. Wiviott SD, Braunwald E, McCabe CH, Horvath I, Keltai M, Herrman JP, Van de Werf F, Downey WE, Scirica BM, Murphy SA, Antman EM TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet 2008;371:1353-1363.
27. Steinberg DH, Mishra S, Javaid A, Pinto Slottwo TL, Buch AN, Roy P, Okabe T, Smith KA, Torguson R, Xue Z, Pichard AD, Satler LF, Kent KM, Suddath WO, Waksman R. Comparison of effectiveness of bare metal stents versus drug-eluting stents in large (≥3.5 mm) coronary arteries. Am J Cardiol 2007;99:599-602.
28. Pfisterer M, Bertel O, Bonetti P, Brunner-La Rocca HP, Eberli FR, Erne P, Galatius S, Hornig B, Kiowski W, Pachinger O, Pedrazzini G, Rickli H, De Servi S, Kaiser C BASKET-PROVE Investigators. Drug-eluting vs. bare-metal stents in large coronary vessel stenting. The BASKET-PROVE trial: study protocol and design. Am Heart J 2008;155:609-614.